Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Have hidradenitis suppurativa (HS) for at least 1 year (365 days) prior to the baseline visit as determined by the investigator through participant interview and/or review of the medical history~* Have Hurley Stage II or Hurley Stage III HS as determined by the investigator at screening and baseline visits~* Have HS lesions present in at least 2 distinct anatomic areas (examples include but are not limited to left and right axilla; or left axilla and left inguinocrural fold) at screening and baseline visits~* Have a total abscess and inflammatory nodule (AN) count of greater than or equal to (\>=) 5 at the screening and baseline visit~* Agree not to receive a live virus or live bacterial vaccination during the study and for 90 days after the last administration of study intervention~Exclusion Criteria:~* Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances~* Has unstable cardiovascular disease, defined as a recent clinical deterioration (that is, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months~* Has or has had herpes zoster within the 2 months before screening~* Has a transplanted organ (with exception of a corneal transplant greater than \[\>\] 3 months before the first administration of study intervention)~* Has known allergies, hypersensitivity, or intolerance to bermekimab or adalimumab or its excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Group 1): Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo subcutaneously (SC) at Week 0 through Week 15. At Week 16, participants will cross over to receive bermekimab dose 1 SC every week thereafter through Week 31.
- Part 1 (Group 2): Adalimumab (Type: ACTIVE_COMPARATOR): Participants will receive adalimumab 160 milligrams (mg) SC at Week 0, placebo SC at Week 1, followed by adalimumab 80 mg SC and placebo SC at Weeks 2 and 3. Participants will then receive adalimumab 40 mg SC and placebo SC at Week 4 and every week thereafter through Week 31.
- Part 1 (Group 3): Bermekimab Dose 1 (Type: EXPERIMENTAL): Participants will receive bermekimab dose 1 SC and placebo SC at Week 0, followed by bermekimab dose 1 SC at Week 1 and every week thereafter through Week 31.
- Part 2 (Group 1): Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo SC from Week 0 through Week 11. At Week 12, participants will cross over to receive bermekimab dose 1 SC weekly through Week 31.
- Part 2 (Group 2): Bermekimab Dose 1 (Type: EXPERIMENTAL): Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 31.
- Part 2 (Group 3): Bermekimab Dose 1 (Type: EXPERIMENTAL): Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 1 SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
- Part 2 (Group 4): Bermekimab Dose 2 (Type: EXPERIMENTAL): Participants will receive bermekimab dose 2 SC and placebo SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 2 SC and placebo SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.

Based on this trial design, predict the completion outcome and termination type (if applicable).